Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||anti-thymocyte globulin + Busulfan + Fludarabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Busulfan||Busulfex||Busulphan||Busulfex (busulfan) inhibits DNA replication and RNA transcription, likely through induction of DNA alkylation (PMID: 27481448). Busulfex (busulfan) in combination with cyclophosphamide is FDA approved as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for patients with chronic myelogenous leukemia (FDA.gov).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|anti-thymocyte globulin||Thymoglobulin||lymphocyte immune globulin|ATGAM||Thymoglobulin (anti-thymocyte globulin) is an immunoglobulin that binds to and destroys T-lymphocytes, which may aid in reduction of graft-vs-host disease when administered with stem cell transplantation (PMID: 32624582).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT00679536||Phase Ib/II||anti-thymocyte globulin + Busulfan + Fludarabine||Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors||Unknown status|
|NCT01823198||Phase Ib/II||Methotrexate anti-thymocyte globulin + Busulfan + Fludarabine Tacrolimus Filgrastim||Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies||Active, not recruiting|